Similarly to CLL, in AML the promoter of genes coding for Wnt antagonists (sFRP1, sFRP2, sFRP4, sFRP5, DKK1, and DKK3 etc.)are frequently methylated predicting poor outcome in patients (Jost et al., 2008; Valencia et al., 2009). This evidence concerns the gene SFRP2 and B-cell chronic lymphocytic leukemia.